article Open AccessTop 10% cited

Circulating Tumor Cells in Patients with Breast Cancer Dormancy

Clinical Cancer Research · 2004 · Vol. 10(24) · pp. 8152–8162

Songdong Meng✉Debasish Tripathy(Susan G. Komen Breast Cancer Foundation)Eugene P. Frenkel(Susan G. Komen Breast Cancer Foundation)Sanjay Shete(The University of Texas MD Anderson Cancer Center)Elizabeth Z. Naftalis(The University of Texas Southwestern Medical Center)James F. Huth(The University of Texas Southwestern Medical Center)Peter D. BeitschMarilyn Leitch(The University of Texas Southwestern Medical Center)Susan Hoover(The University of Texas Southwestern Medical Center)David Euhus(The University of Texas Southwestern Medical Center)Barbara Haley(Susan G. Komen Breast Cancer Foundation)Larry E. MorrisonTimothy P. Fleming(Washington University in St. Louis)Dorothee Herlyn(The Wistar Institute)Leon W.M.M. Terstappen(Eon Corporation (United States))Tanja Fehm(University of Tübingen)Thomas F. TuckerNancy LaneJianqiang WangJonathan W. Uhr

View via DOI Full-text PDF

Abstract

The CTCs that are dying must be replenished every few hours by replicating tumor cells somewhere in the tissues. Hence, there appears to be a balance between tumor replication and cell death for as long as 22 years in dormancy candidates. We conclude that this is one mechanism underlying tumor dormancy.

Cancer Cells and Metastasis Metastasis and carcinoma case studies Cancer, Stress, Anesthesia, and Immune ResponseBreast cancerDormancyMedicineCirculating tumor cellMastectomyCancerOncologyInternal medicineImmunophenotypingDisease

MeSH terms

AdultAgedBreast NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedNeoplastic Cells, CirculatingNeoplasm Recurrence, LocalBiomarkers, TumorMastectomy, RadicalCase-Control StudiesImmunophenotypingIn Situ Hybridization, FluorescenceNeoplasm, Residual

Citations

969

FWCI

9.69

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Natural Innate and Adaptive Immunity to Cancer